Botulinum toxin - Mapi Pharma
Latest Information Update: 08 Mar 2024
Price :
$50 *
At a glance
- Originator Mapi Pharma
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Urinary incontinence
Most Recent Events
- 06 Feb 2024 Botulinum toxin - Mapi Pharma is available for licensing as of 06 Feb 2024. https://mapi-pharma.com/about/our-strategy/
- 05 Feb 2024 Preclinical trials in Urinary incontinence in Israel (Parenteral), before January 2024 (Mapi Pharma pipeline, January 2024)